ERYPRO IU
Main information
- Trade name:
- ERYPRO IU 1ML VIAL
- Active ingredient:
- Recombinant Human Erythropoietin
- Available from:
- Biocon
- Dosage:
- 4000U/ML
- Pharmaceutical form:
- VIAL
- Composition:
- 1ML
- Medicine domain:
- Humans
- Medicine type:
- Allopathic drug
Documents
- for the general public:
- The information leaflet for this product is not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain it.
Request the information leaflet for the general public.
- for healthcare professionals:
- The information leaflet for this product is not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain it.
Request the information leaflet for healthcare professionals.
Localization
- Available in:
-
India
- Language:
- English
Other information
Status
- Source:
- Central Drugs Standard Control Organization
- Last update:
- 09-08-2016
- The information leaflet for this product is not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain it.
Request the information leaflet for the general public.
- Access to this document is only available to registered users.
Register now for full access
23-4-2018

Human medicines European public assessment report (EPAR): Isentress, raltegravir, Revision: 32, Authorised
Europe - EMA - European Medicines Agency
23-4-2018

Human medicines European public assessment report (EPAR): Feraccru, ferric maltol, Revision: 5, Authorised
Europe - EMA - European Medicines Agency
20-4-2018

Human medicines European public assessment report (EPAR): Vemlidy, tenofovir alafenamide, Revision: 3, Authorised
Europe - EMA - European Medicines Agency
20-4-2018

Opinion/decision on a Paediatric investigation plan (PIP): Flublok, Trivalent, seasonal, recombinant influenza hemagglutinin vaccine, Therapeutic area: Vaccines/Infectious diseases
Europe - EFSA - European Food Safety Authority EFSA Journal
20-4-2018

Human medicines European public assessment report (EPAR): Xeloda, capecitabine, Revision: 23, Authorised
Europe - EMA - European Medicines Agency
20-4-2018

Veterinary medicine European public assessment report (EPAR): Suvaxyn Circo, porcine circovirus vaccine (inactivated, recombinant), Revision: 0, Authorised
Europe - EMA - European Medicines Agency
19-4-2018

Human medicines European public assessment report (EPAR): Odefsey, emtricitabine / rilpivirine / tenofovir alafenamide, Revision: 11, Authorised
Europe - EMA - European Medicines Agency
19-4-2018

Human medicines European public assessment report (EPAR): Ziagen, abacavir, Revision: 35, Authorised
Europe - EMA - European Medicines Agency
19-4-2018

Human medicines European public assessment report (EPAR): Celsentri, maraviroc, Revision: 21, Authorised
Europe - EMA - European Medicines Agency
19-4-2018

Human medicines European public assessment report (EPAR): Nimenrix, meningococcal group A, C, W 135 and Y conjugate vaccine, Revision: 22, Authorised
Europe - EMA - European Medicines Agency
19-4-2018

Human medicines European public assessment report (EPAR): Ameluz, 5-aminolevulinic acid hydrochloride, Revision: 11, Authorised
Europe - EMA - European Medicines Agency
19-4-2018

Human medicines European public assessment report (EPAR): Memantine ratiopharm, memantine, Revision: 5, Authorised
Europe - EMA - European Medicines Agency
18-4-2018

Human medicines European public assessment report (EPAR): Fuzeon, enfuvirtide, Revision: 19, Authorised
Europe - EMA - European Medicines Agency
18-4-2018

Human medicines European public assessment report (EPAR): Cubicin, daptomycin, Revision: 28, Authorised
Europe - EMA - European Medicines Agency
18-4-2018

Human medicines European public assessment report (EPAR): Ritemvia, rituximab, Revision: 3, Authorised
Europe - EMA - European Medicines Agency
18-4-2018

Human medicines European public assessment report (EPAR): Daptomycin Hospira, daptomycin, Revision: 2, Authorised
Europe - EMA - European Medicines Agency
18-4-2018

Opinion/decision on a Paediatric investigation plan (PIP): -, Recombinant human epidermal growth factor, Therapeutic area: Endocrinology, -gynacology-fertility-metabolism
Europe - EFSA - European Food Safety Authority EFSA Journal
18-4-2018

Human medicines European public assessment report (EPAR): Truxima, rituximab, Revision: 5, Authorised
Europe - EMA - European Medicines Agency
18-4-2018

Human medicines European public assessment report (EPAR): Rituzena (previously Tuxella), rituximab, Revision: 4, Authorised
Europe - EMA - European Medicines Agency
18-4-2018

Human medicines European public assessment report (EPAR): Blitzima, rituximab, Revision: 3, Authorised
Europe - EMA - European Medicines Agency
17-4-2018

Human medicines European public assessment report (EPAR): Bosulif, bosutinib, Revision: 13, Authorised
Europe - EMA - European Medicines Agency
17-4-2018

Opinion/decision on a Paediatric investigation plan (PIP): Bexsero, Recombinant Neisseria meningitidis group B NHBA fusion protein / recombinant Neisseria meningitidis group B NadA protein / recombinant Neisseria meningitidis group B fHbp fusion protei
Europe - EFSA - European Food Safety Authority EFSA Journal
17-4-2018

Opinion/decision on a Paediatric investigation plan (PIP): -, Recombinant Clostridium difficile toxoid A / recombinant Clostridium difficile toxoid B, Therapeutic area: Vaccines
Europe - EFSA - European Food Safety Authority EFSA Journal
16-4-2018

Human medicines European public assessment report (EPAR): Simponi, golimumab, Revision: 29, Authorised
Europe - EMA - European Medicines Agency
16-4-2018

Human medicines European public assessment report (EPAR): Taltz, ixekizumab, Revision: 4, Authorised
Europe - EMA - European Medicines Agency
16-4-2018

Human medicines European public assessment report (EPAR): Respreeza, human alpha1-proteinase inhibitor, Revision: 3, Authorised
Europe - EMA - European Medicines Agency
16-4-2018

Human medicines European public assessment report (EPAR): Tasigna, nilotinib, Revision: 32, Authorised
Europe - EMA - European Medicines Agency
13-4-2018

Human medicines European public assessment report (EPAR): Aldara, imiquimod, Revision: 23, Authorised
Europe - EMA - European Medicines Agency
13-4-2018

Human medicines European public assessment report (EPAR): Tecentriq, atezolizumab, Revision: 2, Authorised
Europe - EMA - European Medicines Agency
13-4-2018

Human medicines European public assessment report (EPAR): Menveo, meningococcal group A, C, W-135 and Y conjugate vaccine, Revision: 22, Authorised
Europe - EMA - European Medicines Agency
13-4-2018

Human medicines European public assessment report (EPAR): Marixino (previously Maruxa), memantine, Revision: 6, Authorised
Europe - EMA - European Medicines Agency
13-4-2018

Human medicines European public assessment report (EPAR): Potactasol, topotecan, Revision: 6, Authorised
Europe - EMA - European Medicines Agency
13-4-2018

Human medicines European public assessment report (EPAR): Saxenda, liraglutide, Revision: 4, Authorised
Europe - EMA - European Medicines Agency
13-4-2018

Human medicines European public assessment report (EPAR): Ravicti,  glycerol phenylbutyrate, Revision: 6, Authorised
Europe - EMA - European Medicines Agency
13-4-2018

Human medicines European public assessment report (EPAR): Latuda, lurasidone, Revision: 13, Authorised
Europe - EMA - European Medicines Agency
12-4-2018

Human medicines European public assessment report (EPAR): Esbriet, pirfenidone, Revision: 20, Authorised
Europe - EMA - European Medicines Agency
12-4-2018

Human medicines European public assessment report (EPAR): Torisel, temsirolimus, Revision: 27, Authorised
Europe - EMA - European Medicines Agency
12-4-2018

Human medicines European public assessment report (EPAR): Zelboraf, vemurafenib, Revision: 17, Authorised
Europe - EMA - European Medicines Agency
12-4-2018

Human medicines European public assessment report (EPAR): Cinryze, C1 inhibitor (human), Revision: 16, Authorised
Europe - EMA - European Medicines Agency
12-4-2018

Human medicines European public assessment report (EPAR): Zydelig, idelalisib, Revision: 12, Authorised
Europe - EMA - European Medicines Agency
12-4-2018

Human medicines European public assessment report (EPAR): Leflunomide ratiopharm, leflunomide, Revision: 12, Authorised
Europe - EMA - European Medicines Agency
11-4-2018

Human medicines European public assessment report (EPAR): Ocrevus, ocrelizumab, Revision: 1, Authorised
Europe - EMA - European Medicines Agency
11-4-2018

Human medicines European public assessment report (EPAR): Teysuno, tegafur / gimeracil / oteracil, Revision: 15, Authorised
Europe - EMA - European Medicines Agency
11-4-2018

Human medicines European public assessment report (EPAR): Xtandi, enzalutamide, Revision: 13, Authorised
Europe - EMA - European Medicines Agency
11-4-2018

Human medicines European public assessment report (EPAR): Lutathera, lutetium (177Lu) oxodotreotide, Revision: 1, Authorised
Europe - EMA - European Medicines Agency
11-4-2018

Human medicines European public assessment report (EPAR): Constella, linaclotide, Revision: 15, Authorised
Europe - EMA - European Medicines Agency
11-4-2018

Human medicines European public assessment report (EPAR): Bexsero, meningococcal group-B vaccine (rDNA, component, adsorbed), Revision: 17, Authorised
Europe - EMA - European Medicines Agency
11-4-2018

Human medicines European public assessment report (EPAR): Evotaz, atazanavir / cobicistat, Revision: 6, Authorised
Europe - EMA - European Medicines Agency
11-4-2018

Human medicines European public assessment report (EPAR): Herceptin, trastuzumab, Revision: 33, Authorised
Europe - EMA - European Medicines Agency
11-4-2018

Orphan designation: Adenovirus-associated viral vector serotype 8 containing the human RPGR gene, for the: Treatment of retinitis pigmentosa
Europe - EMA - European Medicines Agency
11-4-2018

Orphan designation: Recombinant human monoclonal antibody against mannan-binding lectin-associated serine protease-2, for the: Treatment of primary IgA nephropathy
Europe - EMA - European Medicines Agency
11-4-2018

Orphan designation: Human monoclonal IgG2 antibody against tissue factor pathway inhibitor, for the: Treatment of haemophilia A
Europe - EMA - European Medicines Agency
11-4-2018

Human medicines European public assessment report (EPAR): Bondronat, ibandronic acid, Revision: 25, Authorised
Europe - EMA - European Medicines Agency
11-4-2018

Human medicines European public assessment report (EPAR): Bonviva, ibandronic acid, Revision: 23, Authorised
Europe - EMA - European Medicines Agency
20-4-2018

Wilate (von Willebrand Factor/Coagulation Factor VIII Complex (Human)) - updated on RxList
US - RxList
18-4-2018

EU/3/18/2007 (Dr Philippe Moullier)
EU/3/18/2007 (Active substance: Adeno-associated viral vector serotype 8 containing the human acid alpha-glucosidase gene) - Orphan designation - Commission Decision (2018)2403 of Wed, 18 Apr 2018 European Medicines Agency (EMA) procedure number: EMA/OD/255/17
Europe -DG Health and Food Safety
18-4-2018

EU/3/18/2008 (StolmAr and Partner PatentanwAlte PartG mbB)
EU/3/18/2008 (Active substance: Adeno-associated viral vector serotype 9 encoding miRNA against human superoxide dismutase 1) - Orphan designation - Commission Decision (2018)2404 of Wed, 18 Apr 2018 European Medicines Agency (EMA) procedure number: EMA/OD/254/17
Europe -DG Health and Food Safety
18-4-2018
![HYPERRHO S/D FULL DOSE (Rho(D) Immune Globulin (Human)) Solution [GRIFOLS USA, LLC]](/web/assets/global/img/flags/us.png)
HYPERRHO S/D FULL DOSE (Rho(D) Immune Globulin (Human)) Solution [GRIFOLS USA, LLC]
Updated Date: Apr 18, 2018 EST
US - DailyMed
18-4-2018
![HYPERRAB (Rabies Immune Globulin (Human)) Injection, Solution [GRIFOLS USA, LLC]](/web/assets/global/img/flags/us.png)
HYPERRAB (Rabies Immune Globulin (Human)) Injection, Solution [GRIFOLS USA, LLC]
Updated Date: Apr 18, 2018 EST
US - DailyMed
16-4-2018

FDA Recognition of Public Human Genetic Variant Databases https://go.usa.gov/xQjp5 #MedicalDevice #PrecisionMedicine
FDA Recognition of Public Human Genetic Variant Databases https://go.usa.gov/xQjp5 #MedicalDevice #PrecisionMedicine
FDA - U.S. Food and Drug Administration
16-4-2018

Actrapid (Novo Nordisk A/S)
Actrapid (Active substance: Insulin human (rDNA)) - Centralised - Yearly update - Commission Decision (2018)2301 of Mon, 16 Apr 2018
Europe -DG Health and Food Safety
12-4-2018

Eyebrow-Raising Finding on How Human Communication Evolved
Title: Eyebrow-Raising Finding on How Human Communication EvolvedCategory: Health NewsCreated: 4/10/2018 12:00:00 AMLast Editorial Review: 4/11/2018 12:00:00 AM
US - MedicineNet
11-4-2018

Human Cancer Meds Might Help Save Tasmanian Devils
Title: Human Cancer Meds Might Help Save Tasmanian DevilsCategory: Health NewsCreated: 4/10/2018 12:00:00 AMLast Editorial Review: 4/10/2018 12:00:00 AM
US - MedicineNet